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Abstract
Background: Respiratory burst function resulting in the release of reactive oxygen species such
as superoxide anion (O2
-) from neutrophils is one of the key mechanisms of the innate immune
system, and maladaptive control of this mechanism is thought to play a pivotal role in the
development of pathologies such as acute lung injury and sepsis. Ovine models of these pathologies
are limited by the poor understanding of ovine neutrophil respiratory burst function.
Results: Aspects of ovine neutrophil respiratory burst function to be characterised were: i) the
maximum rate of O2
- generated (Vmax); ii) the time taken to reach Vmax; iii) the total amount of O2
-
generated during the reaction; and iv) the duration of the reaction. As well as for unstimulated
neutrophils, these aspects were also characterised after incubation with a priming agonist (platelet
activating factor [PAF], tumour necrosis factor alpha [TNF-α] and lipopolysaccharides [LPS])
activating agonists (N-formylmethionyl-leucyl-phenylalanine [fMLP] and phorbol 12-myristate 13-
acetate [PMA]) or a combination of a priming and an activating agonist. In the absence of priming
or activating agonists, ovine neutrophils displayed a low level of respiratory burst function which
was not enhanced by either PAF, TNF-α, LPS or fMLP, but was significantly enhanced by PMA. The
PMA-induced respiratory burst function was further enhanced by pre-incubation with PAF, but not
with TNF-α or LPS. By varying the length of pre-incubation with PAF it was demonstrated that this
effect decreased as the duration of pre-incubation with PAF increased, and that PAF was enhancing
PMA's effects rather than PMA enhancing PAF's effects.
Conclusion: This study successfully adapted a commonly used method of measuring human
neutrophil respiratory burst function to characterise different aspects of ovine neutrophil
respiratory burst function. This improved understanding of ovine neutrophils will facilitate the
validitation of ovine biomedical models of human pathologies in which neutrophils have been
implicated.
Background
Neutrophils comprise one of the major cellular compo-
nents of the innate immune system. They are rapidly
recruited to sites of infection and their response includes
phagocytosis of the injurious element, the release of pre-
formed granular enzymes and proteins and the de novo
production of a range of potentially damaging but
ephemeral, reactive oxygen species (ROS) such as super-
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oxide anion (O2
-) [1]. ROS are generated by a variety of
intracellular mechanisms, although the predominant
mechanism, referred to as respiratory burst, is based upon
the assembly and activation of Nicotinamide Adenine
Dinucleotide Phosphate (NADPH) oxidase which then
catalyses the univalent reduction of molecular oxygen
(O2) to O2
- [1-4].
In healthy individuals this process is closely regulated as
the inappropriate release of ROS by neutrophils can cause
damage to the surrounding tissue and is thought to be a
key factor in the development of pathologies such as acute
lung injury (ALI) and its most severe form, acute respira-
tory distress syndrome (ARDS), as well as the multiple
organ failure characteristic of sepsis. As the scope for
investigating these pathologies in humans is limited, the
development of relevant in-vivo animal models is crucial
in attempting to elucidate the mechanisms by which they
develop. Ovine models have been extensively used in the
study of ALI/ARDS [5-13] and sepsis [14-22], however
they are limited by a lack of understanding of the ovine
neutrophil which has been less well studied than its
human counterpart. Due to the neutrophil's central role
in innate immunity and its postulated role in pathologies
such as ALI/ARDS and sepsis, a better understanding of
ovine neutrophils is crucial to improving the validity of
these ovine biomedical models as well as improving the
understanding of immunology and pathology in sheep.
Respiratory burst function provides a key measure of neu-
trophil function, and studies investigating this have used
different techniques such as luminometry, fluorometry,
precipitation reactions and photometry [23], some of
which have been adapted to study ovine neutrophil respi-
ratory burst function [23-38]. Photometric assays based
upon the superoxide dismutase- (SOD) inhibitable reduc-
tion of cytochrome c have been well standardised for the
measurement of human neutrophil respiratory burst func-
tion. Aspects such as the agonists used and their concen-
trations and incubation times, as well as which parts of
the human neutrophil respiratory burst function that the
assays measure are of importance, with the standard ago-
nists being Platelet Activating Factor (PAF) and N-formyl-
methionyl-leucyl-phenylalanine (fMLP), and the
maximum rate of O2
- release (Vmax) as the standard meas-
ure [1,39-42].
There have been several studies that have used photomet-
ric methods to investigate the respiratory burst function of
neutrophils isolated from the blood of healthy sheep
[24,26,28,29,34,37,43], however differences in assay
methodology, agonists, and in the units measured have
hindered comparisons between the studies. The relevance
of results from these studies has also been hampered by
the technical limitations of the assay protocols used. Stop-
ping the cytochrome c reduction by cold-fixing the cells
[24,37] or simply by not taking any further readings
[28,29] means that these assays do not measure the reac-
tion reaching its natural completion, and may bias the
assay towards faster reacting agonists. The technique of
measuring SOD-inhibitable reduction of cytochrome c
has not been utilised to characterise the ovine neutrophil
respiratory burst response to biologically relevant agonists
such as lipopolysaccharides (LPS), the purified endotoxin
from Escherichia coli which is used in sheep models of sep-
sis [14-16], and the inflammatory cytokine, Tumour
Necrosis Factor-alpha (TNF-α), which is released from
monocytes and tissue macrophages in response to LPS,
PAF and other agonists [44,45]. Priming, a process in
which the response of neutrophils to an activating agonist
is enhanced by prior exposure to a priming agonist, has
been well-characterised in human neutrophils [1,37,46-
57], but with the exception of Buchta's paper [24], there
has been little investigation into the effects that combina-
tions of agonists have on ovine neutrophil respiratory
burst function.
This paper aimed to take a standard human neutrophil
respiratory burst assay [58,59] and adapt it for the meas-
urement of ovine neutrophil respiratory burst function.
This assay would also be adapted to measure not just the
maximum rate of the reaction (Vmax), but also the total
amount of O2
- generated during the reaction, the length of
the reaction and the time taken to reach Vmax thus allow-
ing us to better characterise neutrophil respiratory burst
function. This modified assay could then be used to define
changes in ovine neutrophil respiratory burst function in
response to a range of agonists, and by using these ago-
nists both individually and in combination, it was possi-
ble to determine if sheep neutrophils demonstrate a
response analogous to the priming and activation demon-
strated in human neutrophils.
Results
Neutrophil isolation
Whole blood collected from sheep had an average neu-
trophil count of 2.70 ± 3.50 × 109 cells/L (average ± stand-
ard deviation). The average neutrophil yield of the
isolations was 35.21 ± 16.76% of starting numbers of
neutrophils, with an average purity of 83.81 ± 8.70% neu-
trophils in the total leucocyte population, an average
erythrocyte contamination of 0.004 ± 0.007 × 1012 cells/L,
and an average platelet contamination of 19.89 ± 22.59 ×
109 cells/L.
Assessment of respiratory burst stimulation by a single 
agonist
The respiratory burst function of isolated ovine neu-
trophils was assessed with either a priming or an activat-
ing agonist or with a control (nil) in which buffer only
was used, and these results are shown in Table 1. Maxi-
mum rate (Vmax) results are reported as nmoles O2
- per 2 ×BMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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105 neutrophils per minute, and results for total O2
- are
reported as nmoles O2
- per 2 × 105 neutrophils. Unstimu-
lated neutrophils had a low level of respiratory burst func-
tion, with an average Vmax of 0.216 ± 0.113 nmol O2
-/2 ×
105 neutrophils/min (average ± SD) and an average total
O2
- of 1.884 ± 1.527. This result indicates that the cells
were not activated during isolation or testing, and that
resting ovine neutrophils display low levels of respiratory
burst function.
When incubated individually with ovine neutrophils each
of the priming agonists: PAF, TNF-α, and LPS displayed
low levels of respiratory burst function with Vmax values of
0.558 ± 0.307 nmol O2
-/2 × 105 neutrophils/min, 0.340 ±
0.213 nmol O2
-/2 × 105 neutrophils/min, and 0.652 ±
0.363 nmol O2
-/2 × 105 neutrophils/min respectively; and
with total O2
- values of 2.657 ± 1.955 nmol O2
-/2 × 105
neutrophils, 1.257 ± 0.485 nmol O2
-/2 × 105 neutrophils,
and 1.105 ± 0.443 nmol O2
-/2 × 105 neutrophils respec-
tively. This did not represent a significant increase in res-
piratory burst function compared to unstimulated ovine
neutrophils for any of the agonists (P > 0.05 for both Vmax
and total O2
- for each of the agonists).
Of the activating agonists phorbol 12-myristate 13-acetate
(PMA) produced the strongest response with an average
Vmax of 1.222 ± 0.532 nmol O2
-/2 × 105 neutrophils/min
and an average total O2
- of 24.340 ± 4.264 nmol O2
-/2 ×
105 neutrophils. This represented a significant increase in
respiratory burst function compared to unstimulated
ovine neutrophils (P < 0.001 for both Vmax and total O2
-).
Analyses of the time taken to reach Vmax (14.38 ± 7.30
min) and the length of the reaction (58.66 ± 20.55 min)
showed that the PMA-induced respiratory burst was a
slow reaction with a long duration. The other activating
agonist, fMLP, produced a weaker response with an aver-
age Vmax of 0.567 ± 0.288 nmol O2
-/2 × 105 neutrophils/
min and an average total O2
- generated of 1.688 ± 1.453
nmol O2
-/2 × 105 neutrophils. This did not represent a sig-
nificant increase in respiratory burst function compared




In order to investigate the ability of combinations of ago-
nists to enhance the respiratory burst function of ovine
neutrophils, cells were incubated firstly with a priming
agonist before the subsequent addition of an activating
agonist. PMA was added following a 10 minute incuba-
tion with either PAF or TNF-α, or following a 60 minute
incubation with LPS (Fig 1A and 1B), and fMLP was
added after a 10 minute incubation with either PAF or
TNF-α, or after a 60 minute incubation with LPS (Fig 1C
and 1D).
Table 1: Characteristics of ovine neutrophil respiratory burst function in response to a range of priming and activating agonists
nV max
(nmoles O2
-/2 × 105 neutrophils/min)
time to Vmax
(min)
total amount of O2
- released
(nmoles O2
-/2 × 105 neutrophils)
duration of reaction
(min)
Nil 29 mean 0.216 16.0 1.885 65.5***
std dev 0.113 6.9 1.527 33.8
PAF
(20 μM)
28 mean 0.558 11.3** 2.657 27.5
std dev 0.308 23.3 1.956 21.0
TNF-α
(10 ng/mL)
6 mean 0.339 5.3 1.255 72.5
std dev 0.212 7.2 0.484 38.2
LPS
(50 ng/mL)
6 mean 0.650 8.7 1.106 44.2
std dev 0.362 5.8 0.441 32.3
PMA
(20 ng/mL)
26 mean 1.221*** 14.4 24.340*** 58.7
std dev 0.532 7.3 4.264 20.5
fMLP
(20 μM)
28 mean 0.567 5.2*** 1.688 36.4**
std dev 0.288 5.2 1.452 31.5
Ovine neutrophils (2 × 105) were incubated either with buffer only (Nil) or one of a range of priming (PAF, TNF-α, LPS) and activating agents (PMA, 
fMLP). Total assay length was 120 minutes. Parameters were measured as described in Methods. Asterisks represent level of significance compared 
to unstimulated cells (Nil); * p < 0.05; ** p < 0.01; *** p < 0.001.BMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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Compared to ovine neutrophils that were incubated with
PMA alone (1.222 ± 0.532 nmol O2
-/2 × 105 neutrophils/
min [Fig 1A]), there was a significant increase in Vmax (P <
0.001) when the cells were first incubated with PAF for 5
minutes prior to the subsequent addition of PMA (2.408
± 0.888 nmol O2
-/2 × 105 neutrophils/min [Fig 1A]).
There was, however no significant change in total O2
- gen-
erated (from 24.340 ± 4.264 nmol O2
-/2 × 105 neutrophils
for PMA by itself to 23.000 ± 5.752 nmol O2
-/2 × 105 neu-
trophils for PAF followed by PMA; P > 0.05; [Fig 1B]).
Analyses of the time taken to reach Vmax (8.14 ± 6.20 min)
and the duration of the reaction (41.58 ± 24.09 min)
showed no significant change (P > 0.05 in both cases)
when compared to PMA alone.
The PMA-induced respiratory burst response of ovine neu-
trophils showed no significant changes in either Vmax or
total O2
- generated (P > 0.05 in both cases) when the cells
were incubated with TNF-α for 10 minutes (Vmax: 1.028 ±
0.202 nmol O2
-/2 × 105 neutrophils/min [Fig 1A]; total
O2
- generated: 24.490 ± 3.161 nmol O2
-/2 × 105 neu-
trophils [Fig 1B]) or with LPS for 60 minutes (Vmax: 0.956
± 0.293 nmol O2
-/2 × 105 neutrophils/min [Fig 1A]; total
O2
- generated: 19.160 ± 6.276 nmol O2
-/2 × 105 neu-
trophils [Fig 1B]) relative to cells that received PMA only.
There were also no significant changes (P > 0.05 in both
cases) in the time taken to reach Vmax or in the duration of
the reaction relative to cells stimulated with PMA alone
(data not shown).
The fMLP-induced respiratory burst response of ovine
neutrophils showed no significant changes in either Vmax
or total O2
- generated (P > 0.05 in all cases) when the cells
were incubated with PAF for 10 minutes (Vmax: 0.765 ±
0.956 nmol O2
-/2 × 105 neutrophils/min [Fig 1C]; total
O2
- generated: 2.797 ± 1.404 nmol O2
-/2 × 105  neu-
trophils [Fig 1D]), TNF-α for 10 minutes (Vmax: 0.650 ±
0.389 nmol O2
-/2 × 105 neutrophils/min [Fig 1C]; total
O2
- generated: 4.893 ± 6.751 nmol O2
-/2 × 105  neu-
trophils [Fig 1D]) or with LPS for 60 minutes (Vmax: 0.648
± 0.247 nmol O2
-/2 × 105 neutrophils/min [Fig 1C]; total
O2
- generated: 2.458 ± 1.281 nmol O2
-/2 × 105  neu-
trophils [Fig 1D]) relative to cells that received fMLP only
(Vmax: 0.567 ± 0.288 nmol O2
-/2 × 105 neutrophils/min
[Fig 1C]; total O2
- generated: 1.688 ± 1.453 nmol O2
-/2 ×
105 neutrophils [Fig 1D]). There were also no significant
changes (P > 0.05 in all cases) in the time taken to reach
Vmax or in the duration of the reaction relative to cells stim-
ulated with fMLP alone (data not shown).
Enhanced Respiratory Burst Function?
In order to investigate whether incubation of ovine neu-
trophils with PAF causes an enhanced respiratory function
following subsequent PMA stimulation, the duration of
incubation was varied and the order of addition was
reversed (i.e. PMA incubation and then addition of PAF)
and results are shown in Figure 2.
When ovine neutrophils were incubated with PAF for 10
minutes prior to the addition of PMA there was an average
Vmax of 2.010 ± 0.775 nmol O2
-/2 × 105 neutrophils/min
(Figure 2A) and an average total O2
- generated of 22.950
± 6.619 nmol O2
-/2 × 105 neutrophils (Figure 2B). When
ovine neutrophils were incubated with both PAF and PMA
simultaneously (i.e. 0 min incubation) there was an aver-
age Vmax of 3.202 ± 1.327 nmol O2
-/2 × 105 neutrophils/
min (Figure 2A) and an average total O2
- generated of
24.990 ± 7.658 nmol O2
-/2 × 105 neutrophils (Figure 2B).
When the order of addition was reversed, and ovine neu-
trophils were incubated with PMA for 10 minutes prior to
the addition of PAF there was an average Vmax of 2.100 ±
0.812 nmol O2
-/2 × 105 neutrophils/min (Figure 2A) and
an average total O2
- generated of 24.660 ± 9.634 nmol O2
-
/2 × 105 neutrophils (Figure 2B).
Figure 2A shows that the strongest change in Vmax  is
observed when PAF and PMA are simultaneously added to
ovine neutrophils, with the magnitude of the response
A comparison of the effects on ovine neutrophil respiratory  burst function when incubated with either a single agonist or  with a combination of agonists Figure 1
A comparison of the effects on ovine neutrophil res-
piratory burst function when incubated with either a 
single agonist or with a combination of agonists. 
Ovine neutrophils were incubated with either a single agonist 
or with a priming agonist (PAF, TNF-α, and LPS incubations 
were for 5, 10 and 60 minutes respectively) and an activating 
agonist (either PMA in A and B, or fMLP in C and D). Vmax (A 
and C) and the total amount of O2
- released (B and D) are 
shown. In A and B, n = 27, 6, 6, 26, 18, 6 and 5 respectively. 
In C and D, n = 27, 6, 6, 28, 20, 6 and 5 respectively. Results 
are shown in the form of a Box and Whiskers graph, and 
groups were compared using one way ANOVA followed by 
post hoc Bonferroni test for multiple comparisons. Signifi-
cance was determined at P < 0.05.BMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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decreasing as the time interval between the two agonists is
increased. Compared to the response to PMA alone, there
is a significantly enhanced response in Vmax for the simul-
taneous addition (P < 0.001) or after either 5 minutes (P
< 0.001) or 10 minutes (P < 0.01), but not when the order
was reversed (P > 0.05). Figure 2B shows that there were
no significant changes in the total amount of O2
- gener-
ated for ovine neutrophils stimulated by PMA when com-
paring cells stimulated by PMA only with those that were
also stimulated with PAF. Figure 2C shows that there was
a decrease in the time taken to reach Vmax when ovine neu-
trophils were incubated with PAF and PMA (in any com-
bination) as compared to PMA alone, however this was
not significant (P > 0.05 in all cases). As shown in Figure
2D, a significant decrease in the duration of the reaction
compared to PMA alone (58.66 ± 20.55 min) was
observed when PAF and PMA were added simultaneously
and when the order was reversed (28.13 ± 18.38 min and
20.61 ± 10.19 min respectively; P < 0.05 in both cases),
but not when PAF was incubated for either 5 or 10 min-
utes before the addition of PMA (41.58 ± 24.09 min and
33.18 ± 16.52 min respectively; P > 0.05 in both cases).
Discussion
The ability of neutrophils to destroy bacteria or other
pathogens is dependant upon their ability to mount an
effective respiratory burst response. The respiratory burst
function is commonly investigated by assays based upon
the SOD-inhibitable reduction of cytochrome c by O2
-.
Changes to the respiratory burst function of isolated
human neutrophils induced by a range of priming and
activating agonists has been well characterised, however
the respiratory burst function of ovine neutrophils has
been less well characterised. There have been fewer reports
of ovine neutrophil respiratory function, and these studies
are limited due to either: the methodology used, the small
number of agonists investigated, or the lack of investiga-
tion into combinations of agonists. This study aimed to
address these limitations by adapting a standardised
method of investigating human neutrophil respiratory
burst function to investigate the changes in ovine neu-
trophil respiratory burst function due to incubation with
a range of agonists, both individually and in combina-
tion.
In previous studies of neutrophil respiratory burst func-
tion the maximum reaction rate or Vmax has been the prin-
cipal measure [1,39,40,58,59]. The current study collected
data on Vmax, but has additionally collected data on the
time taken to reach Vmax, the total amount of O2
- released
during the reaction and the duration of the reaction. This
additional data allowed a more complete characterisation
of the ovine neutrophil respiratory burst function. The
assay used in this study was run for a two hour period as
compared to the 10 – 60 minute time period that previous
studies were run for [24,28,34,37]. This extra time proved
to be important because it allowed the reactions to run to
completion, and allowed sufficient time for the priming
periods previously shown to be optimal for these agonists
[1]. The reaction duration and time taken to reach Vmax
data obtained in this study for PMA-induced ovine neu-
trophil respiratory burst function (Table 1) indicates that
in Buchta's study [24] when these reactions had been
stopped at 10 minutes, the reaction would not have been
completed, and would not have reached Vmax. This would
indicate that Buchta's study may have underestimated the
PMA-induced ovine neutrophil respiratory burst function.
Since the reactions in this study were allowed to run to
completion, with regular readings taken throughout the
assay, the data presented here is likely to be more accurate.
A comparison of the effects on PMA-induced ovine neu- trophil respiratory burst function when varying the length of  PAF incubation, and the order of agonist addition Figure 2
A comparison of the effects on PMA-induced ovine 
neutrophil respiratory burst function when varying 
the length of PAF incubation, and the order of ago-
nist addition. Ovine neutrophils were incubated with either 
a single agonist (PAF or PMA; n = 27 and n = 26 respectively) 
or with a combination of PAF and PMA. Incubation times 
investigated were 0 minutes (simultaneous addition of PAF 
and PMA; n = 19), and both 5 and 10 minutes (PAF followed 
by PMA; n = 18 and n = 21 respectively). The order of addi-
tion was also varied, with PMA being added first, incubated 
for 10 minutes, and then PAF being added (n = 8). Results are 
shown for Vmax (A), time taken to reach Vmax (B), the total 
amount of O2
- released (C), and reaction duration (D). 
Results are shown in the form of a Box and Whiskers graph, 
and groups were compared using one way ANOVA followed 
by post hoc Bonferroni test for multiple comparisons. Signifi-
cance was determined at P < 0.05.BMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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In this study the agonists considered to be priming ago-
nists for human neutrophils (PAF, TNF-α, and LPS) did
not induce a significant change in ovine neutrophil respi-
ratory burst function when added individually. This result
is consistent with those from studies of human neutrophil
respiratory burst function showing that only some prim-
ing agonists are capable of inducing a significant response
of their own, and even then this is only when they are
added in high concentrations that may not be physiolog-
ically relevant [1,60]. Of the two agonists considered to be
activating agonists for human neutrophils (PMA and
fMLP), when added individually only PMA induced any
significant change in ovine neutrophil respiratory burst
function relative to unstimulated cells, with titrations
showing that this response was dose-dependent (data not
shown). The pathways by which PMA and fMLP activate
neutrophil respiratory burst function are different. Studies
of human neutrophils have shown that PMA stimulates
the signalling element, protein kinase c (PKC) directly
whereas fMLP does so indirectly by binding to G-protein
linked receptors on the surface of the neutrophil that sub-
sequently dissociate and activate multiple signalling path-
ways including mitogen -activated protein kinase (MAPK)
and lipid kinases, as well as phospholipases which pro-
duce the second messengers responsible for activation of
PKC [1,2,4].
In humans it has been shown that while some priming
agonists cause an increase in fMLP receptor expression,
the receptor-generated response is generally not the rate-
limiting step in the priming and activation response and
so this does not cause any increased response [3,4,47].
Previous reports have shown that fMLP has a negligible
effect on ovine neutrophil respiratory burst function, and
have hypothesised that this is due to either the low expres-
sion or the absence of receptors for this peptide on the sur-
face of the cell [24,37], so it is possible that this may be a
reaction-limiting step in ovine neutrophils. This study
therefore investigated the possibility that incubation of
ovine neutrophils with a priming agonist prior to the sub-
sequent addition of fMLP would increase the expression
of fMLP receptors to a level at which ovine neutrophil res-
piratory burst function to fMLP could be measured. The
incubation periods and the concentrations used in this
study demonstrated that neither PAF, TNF-α, or LPS was
capable of enhancing ovine neutrophil respiratory burst
function in response to fMLP. This provides evidence sup-
porting the hypothesis that fMLP receptors are not
expressed on the surface of ovine neutrophils, however to
prove this hypothesis conclusively, ovine neutrophil sur-
face expression studies using anti-fMLP receptor antibod-
ies would be required.
Studies into human neutrophil respiratory burst function
have demonstrated that priming agonists act to increase
the response to PMA although the exact mechanisms by
which they act remains uncertain and are thought to vary
for different agonists. PAF is thought to act by enhancing
PKC activity via a calcium-dependent mechanism [60]
whereas TNF-α priming has been demonstrated to be
independent of extracellular calcium [48] and priming of
PMA-induced respiratory burst activity by LPS has not yet
been demonstrated. Based upon these differences in prim-
ing mechanisms for the priming agonists used in this
study, the finding that only PAF appeared to affect the
PMA-induced respiratory burst function of ovine neu-
trophils was not unexpected nor was it novel.
This study demonstrated that there was a significant
increase in Vmax for ovine neutrophils incubated with PAF
followed by PMA or when they were added simultane-
ously but not when incubated with PMA followed by PAF,
however this did not correlate with any significant change
in the total amount of O2
- released during the reactions. In
other words, the total amount of O2
- released in response
to PMA stimulation remained constant regardless of PAF
co-stimulation. It would make sense that if the total
amount of O2
- released during the reaction remains con-
stant while the Vmax increases, then the duration of the
reaction should decrease, however this was found to be
the case only when PAF and PMA were added simultane-
ously and not when there PMA was added after a 5 or 10
minute incubation with PAF. A possible explanation for
this is that the magnitude of PAF-priming of the PMA-
induced respiratory burst function of ovine neutrophils is
at its maximum either immediately or shortly after PAF
addition, and then decreases rapidly over the 10 minute
time period tested here.
This study has provided evidence that PAF is capable of
having an enhanced effect upon the subsequent PMA-
induced respiratory burst function of ovine neutrophils.
Firstly the Vmax  values observed for ovine neutrophils
stimulated by both PAF and PMA was not just greater than
that of either agonist alone but also was greater than the
combined Vmax values obtained by simply adding together
the effects of each agonist alone. Additionally, the Vmax
data presented here indicates that PAF is enhancing PMA-
induced respiratory burst function rather than PMA
enhancing PAF-induced respiratory burst function. Fur-
ther evidence, such as that from blocking studies using
PKC inhibitors or PAF antagonists, would be required to
better elucidate the relationship between PAF and PMA
and to ascertain whether this is analogous to the priming
and activation described for human neutrophils.
These experiments have demonstrated that LPS and TNF-
α did not enhance either fMLP- or PMA-induced ovine
neutrophil respiratory burst function. This is not unex-
pected because even for human neutrophils the PMA-BMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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induced respiratory burst function has not been demon-
strated to be primed by LPS, and the evidence from this
and other studies [24,37] indicates that there is no signif-
icant fMLP-induced ovine neutrophil respiratory burst
function. So while this study has not been able to demon-
strate priming by either LPS or TNF-α, further studies
using alternative activating agonists may demonstrate
whether LPS and TNF-α are capable of priming ovine neu-
trophil respiratory burst function. Alternatively the inves-
tigation of specific surface molecule markers of neutrophil
priming and activation would provide a measure of ovine
neutrophil priming and activation independent of respi-
ratory burst function, and this different technique may
also demonstrate whether LPS and TNF-α are capable of
priming ovine neutrophils.
Studies to define the role of endogenous PAF in ovine bio-
medical models have trialled PAF-receptor antagonists
with mixed results [61,62], so an alternative method of
assessing this would be beneficial. While PMA is not a bio-
logically relevant agonist, its characterisation here and in
other studies [24,34] has demonstrated that it is useful as
an in-vitro activating agonist for the ovine neutrophil res-
piratory burst function. The possibility that PAF may be
capable of enhancing or priming the ovine neutrophil res-
piratory burst function for subsequent activation by PMA
is an important finding because it means that it may be
possible to investigate endogenous PAF priming of ovine
neutrophils by isolating them and stimulating them with
PMA. It has been demonstrated in humans that neu-
trophils isolated from injured or sick patients display a
reduced respiratory burst function in response to priming
and activating agonists as compared to healthy controls
[58,59], so by using the assay described in this study with
the agonists PAF and PMA, it may be possible to investi-
gate whether neutrophils isolated from sick or injured
sheep display a similar reduced respiratory burst function.
This would greatly enhance the relevance of ovine bio-
medical models of human pathologies such as ALI/ARDS
and sepsis. Another way to enhance these models would
be to directly compare the expression of key markers
linked to neutrophil priming and activation on the sur-
faces of both human and ovine neutrophils.
Conclusion
This study has described an assay based upon the SOD-
inhibitable reduction of cytochrome c to measure several
aspects of ovine neutrophil respiratory burst function. The
actions of several well-characterised human neutrophil
priming and activating agonists were investigated both
individually and in combination. It was shown that the
priming agonists PAF, TNF-α and LPS did not on their
own induce the ovine neutrophil respiratory burst. It was
demonstrated that fMLP, both on its own, and after prim-
ing by either PAF, TNF-α and LPS, did not induce the
ovine neutrophil respiratory burst. PMA, however was
capable of inducing the ovine neutrophil respiratory burst
by itself, and this response was significantly enhanced by
pre-incubation with PAF, with an increase in Vmax and a
decrease in the duration of the reaction. These changes
indicate that PAF in some way, possibly analogous to the
priming described for human neutrophils, enhances the
PMA-induced ovine neutrophil respiratory burst. The
findings of this study advance our knowledge and under-
standing of ovine neutrophils, and improve the validity of
ovine biomedical models of human pathologies such as




To minimise the likelihood of isolated neutrophils
becoming inadvertently primed or activated during isola-
tion or testing all the solutions and materials used in this
study were sterile or endotoxin-free. Cytochrome C, SOD,
PAF, LPS, TNF-α, Phorbol 12-Myristate 13-Acetate (PMA)
and fMLP were obtained from Sigma (Castle Hill, Aus-
tralia) and were diluted into stock solutions that were
stored at -80°C. Working solutions were obtained on the
day of assay by dilution of stock solutions in Hanks' buff-
ered salt solution containing calcium, magnesium and
glucose (HCMG; Gibco, Invitrogen, Auckland, New Zea-
land).
Animals and sample collection
This study has been approved by the University Animal
Ethics Committee (The University of Queensland, Bris-
bane, Australia). The sheep used in this study were Merino
ewes, housed in outdoor pens. Fifty-six blood samples (25
– 100 mL) from 38 different sheep were collected from
either the right or left jugular vein. Blood samples were
collected into syringes and immediately transferred into
sodium citrate tubes (Becton Dickinson, Macquarie, Aus-
tralia).
Isolation of ovine neutrophils
Neutrophils were isolated from fresh ovine whole blood
in a method adapted from previously published methods
of ovine and human neutrophil isolation [1,24,34,37].
Whole blood was centrifuged at 400 g for 30 min. Platelet
rich plasma was discarded, and the buffy coat and packed
cell volume was pooled. Erythrocytes were lysed by hypo-
tonic lysis with 10 mL packed cells gently mixed with 36
mL water for 20 seconds before isotonicity was restored
with the addition of 4 mL of 9% sodium chloride (Ajax
Fine Chemicals, Taren Point, Australia). Leucocytes were
recovered following centrifugation at 600 g for 5 min,
washed three times in Hanks' buffered salt solution
(HBSS; Invitrogen, Auckland, New Zealand), and then
recovered in HBSS. This leucocyte preparation was thenBMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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underlaid with equal volumes of Ficoll Paque™ Plus (GE
Healthcare, Uppsala, Sweden) and then Mono-Poly
Ficoll-Hypaque Resolving Medium (MP Biomedicals,
LLC, Ohio, USA), and centrifuged at 600 g for 20 minutes.
After centrifugation two leucocyte layers were visible at
the interfaces between the buffer, the Ficoll Paque™ Plus,
and the Mono-Poly Ficoll-Hypaque Resolving Medium,
with the upper layer containing mononuclear leucocytes
and any remaining platelets, and the lower layer contain-
ing granulocytes, of which the majority will be neu-
trophils. Remaining erythrocytes form a pellet at the
bottom of the tube. The lower layer of neutrophils was
collected and then washed three times in HBSS with cen-
trifugation at 600 g for 5 minutes, and then was finally re-
suspended in HBSS.
Assessments of purity and yield
Aliquots of ovine whole blood and isolated neutrophils
were taken and an automated full blood count and white
blood cell differential was performed using the Abbott
Cell-Dyn 3200 Multiparameter Haematology Analyser
(Abbott Diagnostics Division, North Ryde, Australia).
Purity was assessed based upon the percentage of neu-
trophils in the total leucocyte population of the isolation,
as well as the levels of erythrocyte and platelet contamina-
tion. Yields were calculated by dividing the number of
neutrophils in the final isolation by the number of neu-
trophils in the volume of whole blood collected, and were
expressed as a percentage of the starting numbers. This
method aimed for and achieved leucocyte purity of greater
than 80% neutrophils, with erythrocyte and platelet con-
tamination below 0.05 × 1012/L and 0.5 × 109/L respec-
tively, and with a yield of greater than 30%.
Assessment of respiratory burst function
The assay used to assess respiratory burst function was
modified from that described by Fung et al. and was based
upon the SOD-inhibitable reduction of cytochrome c at
550 nm in microtitre plates [2,4,54]. For each agonist or
combination of agonists, duplicates were tested with a
single well containing SOD as a control. Neutrophils (2 ×
105) were added to a reaction mixture containing HCMG,
and cytochrome c (50 uM) and then incubated at 37°C
with shaking for 2 hours on the Bio-Rad 680 plate reader
(Bio-Rad Laboratories, Hercules, California, USA). Meas-
urements of optical density (OD) at 550 nm were taken at
30 second intervals by the plate reader. After an initial 10
minute incubation period agonists (PAF, TNF-α, LPS,
fMLP, and PMA) were added to the appropriate wells, and
the assay continued for a total of 2 hours. In wells where
combinations of agonists were investigated, the priming
agonist was added first and then after a pre-determined
incubation period the activating agonist was added, and
the assay continued until a total time of 2 hours had been
reached. The incubation times used were those suggested
in the literature, except in the experiments to investigate
the PMA-induced response to PAF incubation [1,58,59].
The average optical density from the duplicate wells less
that of the control (SOD) well was then plotted against
time.
Respiratory burst function was characterised as the maxi-
mal rate of O2
- generation (Vmax) and the total amount of
O2
- generated. Vmax was calculated from the steepest slope
with at least 5 data points using the molar extinction coef-
ficient of 21.1 × 103 mol/L for ferricytochrome c, and was
reported as nmoles O2
- per 2 × 105 neutrophils per minute
(Figure 1). The total amount of O2
- generated was calcu-
lated from the difference between the average OD from
the 5 data points preceding agonist addition and the max-
imum OD for that agonist, again using the molar extinc-
tion coefficient of 21.1 × 103 mol/L for ferricytochrome c,
and was reported as nmoles O2
- per 2 × 105 neutrophils
(Figure 3). Data was also collected for the duration of
reaction, calculated as the time interval between the initial
addition of an agonist and when the maximum OD of the
reaction was reached, and the time to Vmax, calculated as
the time interval between the addition of an agonist and
when the reaction rate reached Vmax, with both of these
values reported in minutes (Figure 3).
To decide upon concentrations of each agonist to use, dif-
ferent concentrations of the priming agonists (PAF, TNF-
α, and LPS) were tested individually and in combination
with a fixed concentration of each of the activating ago-
nists (PMA at 20 ng/mL or fMLP at 20 μM). A concentra-
tion for each priming agonist was then chosen by taking
into account the responses measured for both Vmax and the
total amount of O2
- generated. The activating agonists
were then tested at different concentrations both by them-
selves and with a fixed concentration of each of the prim-
ing agonists (20 μM of PAF, 10 ng/mL of TNF-α, and 50
ng/mL of LPS). In the same manner as for the priming
agonists, a concentration for each activating agonist was
then chosen by taking into account the responses meas-
ured for both Vmax and the total amount of O2
- generated.
In these experiments there were cases where no significant
response was evident regardless of the concentration of
agonist used. When this occurred a concentration was
chosen based upon the results of that agonist with PMA.
In the case of fMLP, a small response was measured, and
a dose was chosen based upon this small response. Subse-
quent statistical analysis revealed this response to not be
significant.
Statistical analyses
Where sufficient numbers of neutrophils were available
assays were run with replicates (2–4 replicates), and an
average value for each of the parameters measured was
then calculated, otherwise assays were run in singlicate.BMC Immunology 2009, 10:25 http://www.biomedcentral.com/1471-2172/10/25
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All values were then imported in GraphPad Prism 4.03 for
Windows (GraphPad Software, San Diego California,
USA) and then the average values for each parameter as
well as standard deviations and 95% confidence intervals
were calculated. Results were then compared using one
way ANOVA followed by post hoc Bonferroni test for mul-
tiple comparisons. Significance was determined at P <
0.05.
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